Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 1, 2025
Deals
Novo, Merck each pay $200M for pipeline additions: Deals Report
Pharmas enter nine-figure upfront deals in metabolic, cardiovascular areas; plus, Bluebird will consider competing buyout offer
BioCentury | Mar 25, 2025
Finance
Sofinnova’s ‘pan-European’ play, China innovation and Trump’s tariff threat — a BioCentury podcast
How Biovelocita became the largest life sciences accelerator in Europe, the latest at FDA and more
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Sep 25, 2024
Product Development
Wave claims early lead in second-generation exon 53 skipping
In BioCentury’s latest Clinical Report, Wave gains on DMD data, plus updates from Daiichi and AZ, Black Diamond, Metsera, Biohaven and more
BioCentury | Apr 18, 2024
Finance
Venture report: Metsera’s $290M launch, Regeneron’s new VC fund
Plus fundings for Asher, Pathios, Outrun and Theolytics
BioCentury | Feb 27, 2024
Data Byte
Survodutide leads GLP-1s in MASH
Phase II data for dual GLP-1/glucagon agonist from BI, Zealand suggest best-in-class potential in metabolic dysfunction-associated steatohepatitis
BioCentury | Dec 2, 2023
Product Development
What a pair of Phase II obesity results could mean for Altimmune, Pfizer
Will Altimmune’s pemvidutide be good enough to attract a partner? And will Pfizer go shopping after latest danuglipron data?
BioCentury | Aug 10, 2023
Product Development
Obesity mechanisms in the clinic: which overlap, and which branch out
Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss
BioCentury | Jun 27, 2023
Product Development
Despite fervor, Lilly’s retatrutide not poised to supplant Mounjaro
Phase II data reveal a marginal efficacy gain but a much worse tolerability profile
BioCentury | May 10, 2023
Deals
May 10 Quick Takes: Bicycle in third radiopharma deal of year
Plus: 15% weight reduction for Boehringer, Zealand Phase II asset and updates from Aviko, DiogenX, Syneos, OliX and more
Items per page:
1 - 10 of 48